IP Verse

Method For Inactivation/Removal Of Coagulation Factors By Precipitation - EP2670429

The patent EP2670429 was granted to Octapharma on Apr 4, 2018. The application was originally filed on Feb 3, 2012 under application number EP12702825A. The patent is currently recorded with a legal status of "Revoked".

EP2670429

OCTAPHARMA
Application Number
EP12702825A
Filing Date
Feb 3, 2012
Status
Revoked
Jul 23, 2021
Grant Date
Apr 4, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJan 4, 2019CMS CAMERON MCKENNA NABARRO OLSWANGADMISSIBLE
BIOTESTDec 21, 2018MEWBURN ELLISADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2005082937
EXAMINATIONWO2007085626
INTERNATIONAL-SEARCH-REPORTEP0987274
INTERNATIONAL-SEARCH-REPORTEP1816201
INTERNATIONAL-SEARCH-REPORTGB906860
OPPOSITIONEP0893450
OPPOSITIONEP0987274
OPPOSITIONEP1816201
OPPOSITIONGB906860
OPPOSITIONWO2005082937
OPPOSITIONWO2007085626
OPPOSITIONWO9943362
OTHERWO2005082937
OTHERWO2007085626

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- STEINBUCH M ET AL, "ISOLEMENT DE L'IMMUNOGLOBULINE IGG DU PLASMA HUMAIN A L'AIDE DE L'ACIDE CAPRYLIQUE//ISOLATION OF IGG IMMUNOGLOBULIN FROM HUMAN PLASMA USING CAPRYLIC ACID", REVUE FRANCAISE D'ETUDES CLINIQUES ET BIOLOGIQUES, EDITIONS MEDICALES FLAMMARION, PARIS, FR, (19691201), vol. 14, no. 10, ISSN 0370-4793, pages 1054 - 1058, XP001197292-
EXAMINATION- WOLBERG ALISA S ET AL, "Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations", AMERICAN JOURNAL OF HEMATOLOGY, NEW YORK, NY, US, (20000901), vol. 65, no. 1, ISSN 0361-8609, pages 30 - 34, XP009191076-
EXAMINATION- WILLIAMS MELANIE ET AL, "Removal of Coagulation Factors by the Gamunex (R)-C Purification Process", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, & ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI); SAN ANTONIO, TX, USA; FEBRUARY 22 -26, 2013, (201302), vol. 131, no. 2, Suppl. S, page AB10, XP009179520
EXAMINATION- LEBING W ET AL, "PROPERTIES OF A NEW INTRAVENOUS IMMUNOGLOBULIN (IGIV-C, 10%) PRODUCED BY VIRUS INACTIVATION WITH CAPRYLATE AND COLUMN CHROMATOGRAPHY", VOX SANGUINIS, S. KARGER AG, BASEL, CH, (20030401), vol. 84, no. 3, doi:10.1046/J.1423-0410.2003.00285.X, ISSN 0042-9007, pages 193 - 201, XP001197282
EXAMINATION- RADOSEVICH M ET AL, "Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance", VOX SANGUINIS, S. KARGER AG, BASEL, CH, (20100101), vol. 98, no. 1, ISSN 0042-9007, pages 12 - 28, XP009141581
INTERNATIONAL-SEARCH-REPORT- Anonymous, "Allgemeine Hinweise", (20100501), URL: http://www.ganzimmun.de/item_doc/lv/allgemeine_hinweise.pdf, (20120807), XP002681510 [X] 1,5,13-15 * page 5, paragraphs 1,2 *-
OPPOSITION- "Allgemeine Hinweise", GANZIMMUN DIAGNOSTICS AG, (20100000), pages 1 - 10, XP055546772-
OPPOSITION- "European Medicines Agency: European Medicines Agency recommends suspension of Octagam in all EU member states", EUROPEAN MEDICINES AGENCY, (20100924), URL: http://www.ema. europa .eu/ema/index.isp?curl=paees/news_ and_ events/news/2010/09/news_ detail_ 0011 23.jsp&mid=WC0b01 ac058004d5c 1, XP055547061-
OPPOSITION- Gary Walsh, "5 Therapeutic proteins: blood products and vaccines", Proteins Biochemistry and Biotechnology, John Wiley & Sons, pages 213 - 218, XP055542799-
OPPOSITION- STEINBUCH et al., "ISOLEMENT DE L'IMMUNOGLOBULINE IGG DU PLASMA HUMAIN A L'AIDE DE L'ACIDE CAPRYLIQUE//ISOLATION OF IGG IMMUNOGLOBULIN FROM HUMAN PLASMA USING CAPRYLIC ACID", Rev. Franc. Etudes. Clin. et Biol., (19691200), vol. 14, no. 10, pages 1054 - 1058, XP001197292-
OPPOSITION- STEINBUCH et al., "ISOLEMENT DE L'IMMUNOGLOBULINE IgG DU PLASMA HUMAIN A L'AIDE DE L'ACIDE CAPRYLIQUE", Rev. Franc. Etudes Clin. Et Biol XIV, (19690000), pages 1054 - 1058, XP055546784-
OPPOSITION- WILIAMS M et al., "Abstract 34 J Allergy Clin Immunol from American Academy of Allergy", Asthma and immunology February 2013 AAAAI Annual Meeting, (20130000), XP055547039-
OPPOSITION- WOLBERG et al., "Coagulation Factor XI Is a Contaminant in Intravenous lmmunoglobulin Preparations", American Journal of Hematology, (20000000), vol. 65, pages 30 - 34, XP055547049-
OPPOSITION- STUCKI et al., "Investigations of prion and virus safety of a new liquid IVIG product", Biologicals, (20080000), vol. 36, no. 4, pages 239 - 247, XP022795227
OPPOSITION- WILLIAMS et al., "34 Removal of Coagulation Factors by the Gamunex (R)-C Purification Process", J. Allergy. Clin. Immunol., (20130200), vol. 131, no. 2, page AB10, XP009179520
OPPOSITION- BURNOUT, "Modern Plasma Fractionation", Transfusion Medicine Reviews, (20070400), vol. 21, no. 2, pages 101 - 117, XP005937803
OPPOSITION- LEBING et al., "PROPERTIES OF A NEW INTRAVENOUS IMMUNOGLOBULIN (IGIV-C, 10%) PRODUCED BY VIRUS INACTIVATION WITH CAPRYLATE AND COLUMN CHROMATOGRAPHY", Vox Sanguinis, (20030000), vol. 84, no. 3, pages 193 - 201, XP001197282
OPPOSITION- Radesovich and Bumouf, "Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance", Vox Sanguinis Volume, (20100100), vol. 98, no. 1, pages 12 - 28, XP055546792
OPPOSITION- RADOSEVICH et al., "Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance", Vox Sanguinis, (20100112), vol. 98, no. 1, pages 12 - 28, XP009141581
OPPOSITION- ETSCHEID et al., "Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products : Proteolytic activity in therapeutic immunoglobulins", Vox Sanguinis, vol. 102, (20120000), pages 40 - 46, (20110506), XP055547072
OTHER- STEINBUCN M. ET AL, "ISOLEMENT DE L'IMMUNOGLOBULINE IGG DU PLASMA HUMAIN A L'AIDE DE L'ACIDE CAPRYLIQUE", REVUE FRANCAISE D'ETUDES CLINIQUES ET BIOLOGIQUES, (196912), vol. 14, no. 10, pages 1054 - 1058, XP001197292-
OTHER- WILLIAMS M. ET AL, "REMOVAL OF COAGULATION FACTORS BY THE GAMUNEX (R)-C PURIFICATION PROCESS", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (201302), vol. 131, no. 2 SUPL, page AB10, XP009179520
OTHER- LEBING W. ET AL, "PROPERTIES OF A NEW INTRAVENOUS IMMUNOGLOBULIN (IGIV-C, 10%) PRODUCED BY VIRUS INACTIVATION WITH CAPRYLATE AND COLUMN CHROMATOGRAPHY", VOX SANGUINIS, (200304), vol. 84, no. 3, pages 193 - 201, XP001197282
OTHER- RADOSEVICH M. ET AL, "INTRAVENOUS IMMUNOGLOBULIN G: TRENDS IN PRODUCTION METHODS, QUALITY CONTROL AND QUALITY ASSURANCE", VOX SANGUINIS, (2010), vol. 98, no. 1, pages 12 - 28, XP009141581

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents